

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
24 February 2022 (24.02.2022)



(10) International Publication Number
WO 2022/040345 A1

(51) International Patent Classification:

A61P 11/00 (2006.01) C07K 16/28 (2006.01)
A61P 17/00 (2006.01) A61K 39/00 (2006.01)

(21) International Application Number:

PCT/US2021/046552

(22) International Filing Date:

18 August 2021 (18.08.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/067,259 18 August 2020 (18.08.2020) US

(71) Applicant: CEPHALON, INC. [US/US]; 145 Brandywine
Parkway, West Chester, PA 19380 (US).

(72) Inventors: BRACKEN, Anna, Mikaela; 15/22-24
Longueville Road, Lane Cove, New South Wales 2066
(AU). CLARKE, Adam; 34 King Street, Riverstone, New
South Wales 2765 (AU). COOKSEY, Bridget, A.; 31
Adams Street, Curl Curl, New South Wales 2096 (AU).
DOYLE, Anthony, Gerard; c/o Teva Pharmaceuticals
Australia Pty. Ltd., Lvl 2, 37 Epping Road, Macquarie Park,
New South Wales 2113 (AU). LIDDAMENT, Mark, Ter-
ence; 11 Myrmong Crescent, Ascot Vale, Victoria 3032
(AU). POLLARD, Matthew; 60 Summerland Place, Pul-
lenvale, Queensland 4069 (AU). POULTON, Lynn; c/o
Teva Pharmaceuticals Australia Pty. Ltd., Lvl 2, 37 Epping
Road, Macquarie Park, New South Wales 2113 (AU). QUI-
GLEY, Anna, Maria, Matilda; c/o Teva Pharmaceuticals
Australia Pty. Ltd., Lvl 2, 37 Epping Road, Macquarie Park,
New South Wales 2113 (AU). ROZENFELD, Julia; c/o
Teva Pharmaceuticals Australia Pty. Ltd., Lvl 2, 37 Epping
Road, Macquarie Park, New South Wales 2113 (AU). SZ-
ABAT, Marta; 2215 Yukon Street, Vancouver, British Co-
lumbia V5Y 1L2 (CA).

(74) Agent: SHEA, Jr., Timothy, J. et al.; Sterne, Kessler,
Goldstein & Fox P.L.L.C., 1100 New York Avenue, NW,
Washington, DC 20005 (US).

(81) Designated States (unless otherwise indicated, for every

kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,

DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN,
KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD,
ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO,
NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW,
SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every

kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments (Rule 48.2(h))
- with sequence listing part of description (Rule 5.2(a))

WO 2022/040345 A1

(54) Title: ANTI-PAR-2 ANTIBODIES AND METHODS OF USE THEREOF

(57) Abstract: The present disclosure provides antibodies and antigen-binding fragments thereof that specifically bind to human PAR-2 and compositions comprising such antibodies or antigen-binding fragments thereof. In a particular aspect, the antibodies or antigen-binding fragments thereof that specifically bind to human PAR-2 block the interaction between a PAR-2 activating ligand and an extracellular domain of PAR-2, and/or blocks PAR-2 activation by a PAR-2 activating ligand. In further aspects, the antibodies or antigen-binding fragments can be used to treat diseases or conditions associated with increased expression of PAR-2 and/or diseases or conditions that can be alleviated by antagonizing activation of PAR-2 by a PAR-2 activating ligand (e.g., airway diseases, skin diseases, cancer, orofacial granulomatosis, inflammatory conditions, and pain associated with various diseases or conditions).